[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemodyalysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemodyalysis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100640162","estimation-of-the-prevalence-of-microcirculatory-dysfunction-in-uremic-cardiopathy-among-dialysis-patients-100640162",false,"NCT07608679","Estimation of the Prevalence of Microcirculatory Dysfunction in Uremic Cardiopathy Among Dialysis Patients","PRE-COCO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients who have been on haemodialysis for at least 6 months\n* Elevated troponin levels \\> 40 ng\u002FL in a sample taken whilst the patient was in a stable condition, dated within the last 3 months\n* Patients capable of understanding the protocol and who have given their written informed consent to participate in the research\n* Patients registered with the National Health Service or eligible for it\n\nExclusion Criteria:\n\n* Age \\> 90 years\n* Patient undergoing daily home haemodialysis\n* Symptomatic stage 3 or 4 peripheral arterial disease\n* Severe hypertrophic cardiomyopathy (genetic or amyloid)\n* Severe valvular heart disease leading to left ventricular remodelling (surgically contraindicated severe aortic stenosis, severe mitral regurgitation, severe aortic regurgitation)\n* Hospitalisation for decompensation\u002Facute heart failure within the last month\n* Acute coronary syndrome and any coronary artery disease requiring angioplasty and\u002For stent implantation within the last 3 months\n* Contraindication to METHERGIN and DOBUTAMINE\n* Patients participating in another clinical research protocol that may affect the research objectives\n* Patients already included in the study\n* Patients under guardianship, curatorship or deprived of their liberty\n* Patients under an activated future protection order\n* Patients under family authorisation\n* Patient under judicial protection\n* Pregnant patient","ALL","18 Years","90 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","Patients with end-stage renal disease have a high burden of cardiovascular mortality, yet ischemic heart disease is often asymptomatic and difficult to diagnose in this population. Recent data suggest that microvascular coronary dysfunction may contribute significantly to myocardial ischemia in dialysis patients, but its true prevalence remains unknown. This study aims to evaluate microcirculatory coronary impairment in hemodialysis patients using invasive coronary angiography with measurement of coronary flow reserve (CFR), index of microcirculatory resistance (IMR). The study will also describe the clinical and biological characteristics associated with microvascular dysfunction in this population, in order to better understand the mechanisms of uremic cardiomyopathy and improve cardiovascular risk stratification.",[27],"Hemodyalysis",[29,30],"microcirculatory disorders","hemodyalysis","NOT_YET_RECRUITING","2026-05-20",{"date":34,"type":35},"2026-05-27","ACTUAL",{"date":37,"type":21},"2027-09",{"date":39,"type":21},"2028-09",{"name":41,"class":42},"Centre Hospitalier Departemental Vendee","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100617392","avf-monitor-poc-proof-of-concept-study-100617392","NCT07318025","AVF-MONITOR POC Proof-of-concept Study","AVF-MONITOR: a New Wearable Device for Vascular Access Monitoring in Hemodialysis Patients - Proof-of-concept Study","AVFMONITOR POC","Inclusion Criteria:\n\n* Provision of informed consent prior to any study specific procedures.\n* Female and\u002For male aged ≥ 18.\n* Patients undergoing HD with a mature and functioning native AVF.\n\nExclusion Criteria:\n\n* Patients with a history of complications related to the AVF in use.\n* Patients who use a graft or catheter to perform HD.\n* Patients with reduced life expectancy (less than 1 year).",{"count":53,"type":21},6,[24],"This is a proof-of-concept single-centre prospective longitudinal interventional study performed in AVF patients under HD treatment at the Nephrology and Dialysis Department of the ASST-Papa Giovanni XXIII (Bergamo, Italy), involving the recording of AVF sounds by the AVF-MONITOR wearable prototype device.\n\nParticipants will undergo a screening and enrollment visit, then follow-up visits for AVF sounds registration will be conducted once a week for all participants, prior to dialysis session, over a period of 8 weeks.",[27],[58,59,60,61,62,63,64,65],"arteriovenous fistula","hemodialysis","vascular access","monitoring","sound recording","proof-of-concept study","prototype device","vascular stenosis","2026-01-12",{"date":68,"type":35},"2026-01-14",{"date":70,"type":21},"2026-03",{"date":72,"type":21},"2026-09",{"name":74,"class":42},"Mario Negri Institute for Pharmacological Research",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":16,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":43},"100603786","assessment-of-mineral-and-bone-disorders-in-kidney-transplant-recipients-100603786","NCT07141043","Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients","New Directions and Perspectives in the Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients","Inclusion Criteria:\n\n1. HD group: Patients undergoing HD for at least 12 months, aged 20-70 years, after signing an informed consent.\n2. KTR group: Patients with successful KTx performed at least 12 months prior to their enrollment, aged 20-70 years old, after signing an informed consent. Subjects will be eligible for inclusion regardless of KTx immunosuppression regimen, pre-transplantation history, history of pre-transplant dialysis, or whether the kidney donation was from a living or deceased donor.\n3. GPO group: men and postmenopausal women diagnosed with primary osteopenia or osteoporosis, aged 50-70 years old, after signing an informed consent.\n\nExclusion Criteria:\n\n1. HD group: Treatment with active bone therapies (excluding calcium and vitamin D); ongoing cancer treatment or recent history of malignancy, cirrhosis, recent major fractures, patients who have received transplants other than kidney, secondary causes of osteoporosis (other than CKD or transplant-related: primary hyperparathyroidism, hyperthyroidism, congenital bone disorders, sarcoidosis, severe bone trauma, malignant tumors, inflammatory bowel disease, endogenous Cushing syndrome, anti-estrogen\u002Fanti-androgen therapy, and anorexia nervosa), pregnancy and breast-feeding.\n2. KTR group: The same as for HD + return to dialysis + acute graft rejection.\n3. GPO group: The same as for HD + diabetes mellitus + prolonged glucocorticoid therapy (\\>7.5 mg Prednisone or equivalent for at least 3 months).",true,"20 Years","70 Years",{"count":86,"type":21},180,"OBSERVATIONAL","This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general population for primary osteoporosis evaluation to enhance the assessment of CKD-MBD.",[27,90,91,92],"Kidney Tansplant","Osteoporosis","CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder",[94,91,95],"CKD-MBD","bone turnover markers","RECRUITING","2025-08-18",{"date":99,"type":35},"2025-08-26",{"date":101,"type":35},"2025-03-19",{"date":103,"type":21},"2027-06",{"name":105,"class":42},"Grigore T. Popa University of Medicine and Pharmacy"]